FutureMeds GmbH

FutureMeds GmbH in Berlin is conducting a strong portfolio in cardiovascular disease, hypertension, lipid disorders, obesity, and chronic kidney disease. These studies are designed to test new treatments and combination approaches that may improve blood pressure control, lower harmful cholesterol, and reduce the risk of serious heart and kidney complications.

• Studies in hypertension, including uncontrolled and resistant forms, focus on better blood pressure management and long-term control.
• Atherosclerotic cardiovascular disease, elevated lipoprotein(a), and high cholesterol are being studied to reduce major cardiovascular events.
• Chronic kidney disease and related outcomes are included in trials aiming to protect kidney function and overall cardiovascular health.
• Obesity and type 2 diabetes research explores whether weight-related therapies can also improve cardiometabolic risk.

The site’s work in this area reflects a broad effort to evaluate treatments that may improve long-term outcomes for people with overlapping heart, kidney, and metabolic conditions.

The site is active in nervous system diseases and mental disorders, with trials addressing migraine, Alzheimer’s disease, insomnia, and major depressive disorder. Research here aims to improve symptom control, support brain health, and evaluate new options for conditions that can significantly affect daily life.

• Migraine studies examine prevention of episodic and chronic attacks.
• Alzheimer’s disease research looks at cognitive outcomes in early disease and biomarker-linked cases.
• Insomnia disorder trials focus on improving sleep quality and related symptoms.
• Major depressive disorder studies assess whether new therapies can ease depressive symptoms and anxious distress.

These trials show a clear interest in both symptom relief and disease-modifying approaches across neurological and psychiatric care.

FutureMeds GmbH is also involved in skin and connective tissue diseases, immune system diseases, and allergy-related research. The site is studying alopecia areata, plaque psoriasis, chronic spontaneous urticaria, neurodermatitis, and allergic rhinitis, with the goal of testing therapies that may improve skin symptoms, reduce itching, and support hair regrowth.

• Alopecia areata trials focus on hair regrowth and long-term treatment tolerability.
• Plaque psoriasis and neurodermatitis research evaluates better control of inflammatory skin symptoms.
• Chronic spontaneous urticaria studies aim to reduce hives and related disease activity.
• Allergic rhinitis work examines immunotherapy approaches for house dust mite allergy.

This area combines immune-focused and dermatologic research, offering options that may improve both visible symptoms and quality of life.

The research portfolio at this site includes respiratory tract diseases, virus diseases, and bacterial infections. Studies cover chronic obstructive pulmonary disease, influenza, respiratory syncytial virus, human metapneumovirus, and tuberculosis, reflecting work aimed at prevention, immune protection, and better disease control.

• COPD research evaluates treatments intended to improve lung-related and broader health outcomes.
• Influenza vaccine studies assess safety and immune response in adults.
• Trials for RSV and human metapneumovirus focus on preventing lower respiratory tract disease in older adults.
• Tuberculosis vaccine research is exploring new ways to strengthen protection in healthy volunteers.

These studies highlight an emphasis on prevention as well as treatment across infectious and respiratory conditions.

At FutureMeds GmbH, trials in digestive system diseases, immune system diseases, and musculoskeletal diseases include ulcerative colitis, polymyalgia rheumatica, and alcohol use disorder. The research is focused on evaluating therapies that may reduce inflammation, improve disease control, and support better daily functioning.

• Ulcerative colitis studies examine new ways to control intestinal inflammation.
• Polymyalgia rheumatica research looks at symptom relief in inflammatory pain conditions.
• Alcohol use disorder trials assess whether new treatments can help reduce alcohol consumption and maintain improvement.
• Additional work spans related inflammatory and immune-mediated disorders with unmet treatment needs.

In this therapeutic area, the site is helping test options that could improve both symptom burden and longer-term disease management.

The site also supports studies in nutritional and metabolic diseases, female urogenital diseases and pregnancy-related conditions, and pain-related disorders. Research includes obesity, overweight, type 2 diabetes, diabetic peripheral neuropathic pain, and menopause-related sleep disturbance, with a focus on improving everyday health and comfort.

• Obesity and overweight trials evaluate therapies that may support weight loss and related health benefits.
• Type 2 diabetes studies are linked to broader cardiometabolic risk reduction.
• Diabetic peripheral neuropathic pain research examines new approaches to pain relief.
• Women’s health work includes sleep disturbances associated with menopause and related quality-of-life concerns.

These trials show a practical focus on conditions that often affect long-term wellbeing, mobility, and daily functioning.